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The PPARα ligand fenofibrate: 
meeting multiple targets in 
diabetic nephropathy
Z Varghese1, JF Moorhead1 and XZ Ruan1
Fibrate peroxisome proliferator-activated receptor (PPAR)-α ligands are 
mainly used as hypolipidemic drugs. But this commentary highlights 
their potential in treating insulin resistance, dyslipidemia, and 
hypertension and in preventing diabetic nephropathy, inflammation, 
and cardiovascular disease. Because diabetes is a major contributor to 
chronic kidney disease and cardiovascular disease, PPAR-α agonists 
may provide greater opportunities for hitting multiple targets in this 
complex metabolic disease.
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Currently, there are more than 177 mil-
lion people with diabetes worldwide, and 
it is projected that this will rise to 360 
million by 2030.1 Considering that 30% 
of these people may develop chronic kid-
ney disease, which is also a major inde-
pendent risk factor for cardiovascular 
disease, it is clear that early detection and 
prevention are the only means of escape 
from this emerging medical catastrophe 
of worldwide proportions. Current treat-
ment protocols involving tight glucose 
and blood pressure control, inhibition of 
the renin–angiotensin system, and lipid 
lowering have achieved only a modest, 
though encouraging, impact in arresting 
the development and progression of dia-
betic nephropathy. Additional strategies 
with multiple drugs seem to be essential 
to deal with this impending pandemic. 
Insulin resistance is a key factor mediating 
vascular injury and nephropathy in type 
2 diabetes mellitus; it has a role in type 1 
as well. It is for this reason that insulin-
microalbuminuria and confer renal and 
cardiovascular protection. However, a 
major factor limiting the use of TZDs 
for their renal and cardiac protection 
in diabetic patients is fl uid retention. It 
has been suggested that TZDs activate 
PPARγ expression at the collecting duct, 
which enhances expression of cell-surface 
epithelial sodium channel α.5 Studies in 
healthy men have shown that pioglita-
zone stimulates plasma renin activity 
that contributes to sodium retention and 
weight gain.
It is in this context that we should pay 
special attention to a study on the db/db 
mouse model of diabetes published in 
this issue of Kidney International by Park 
et al.6, who demonstrate that fenofi brate, 
a PPARα agonist, reduces fasting blood 
glucose, ameliorates insulin resistance, 
reduces hypertrophy of pancreatic islets, 
and reduces urinary albumin excretion. 
Park et al. show that the renal protec-
tion aff orded by fenofi brate may occur 
through the reduction of glomerular 
hypertrophy and mesangial matrix. Th ese 
data suggest that PPARα agonists may 
represent a potential therapeutic target 
in treating type 2 diabetes and its renal 
complications without fl uid retention and 
weight gain.
In 1982 Moorhead and colleagues 
introduced the concept of lipid-medi-
ated renal injury and suggested how 
the pathogenesis of atherosclerosis and 
glomerulosclerosis could have common 
pathways. Th ey have further shown how 
infl ammation could modify lipid-medi-
ated renal injury by increasing cholesterol 
uptake and inhibiting cholesterol effl  ux 
in human mesangial cells and smooth 
muscle cells.7 Lipid-mediated injury plays 
an important role in the pathogenesis of 
many renal diseases, including diabetic 
nephropathy. Diabetic kidneys specifi -
cally expressed several genes normally 
found in adipocytes, including adipose 
diff erentiation-related protein (ADRP, 
or adipophilin in humans), suggesting a 
switch of kidney phenotype in favor of 
lipid accumulation in diabetes.8
It has been demonstrated that PPARs 
play an important role in controlling cel-
lular and whole-body sterol homeo stasis, 
sensitizing thiazolidinediones (TZDs) are 
increasingly used in type 2 diabetes. TZDs 
are ligands for peroxisome proliferator-
activated receptor-γ (PPARγ), a member 
of the ligand-dependent nuclear recep-
tor superfamily. After ligand binding, 
PPARs form heterodimers with retinoid 
X receptor-α and then undergo confor-
mational changes, which facilitate their 
binding to PPAR-responsive elements in 
the nucleus for target gene transcription. 
PPARs play an important role in the gen-
eral transcriptional control of numerous 
cellular processes that are key factors in 
the development of diabetic nephropa-
thy, including glucose homeostasis, lipid 
metabolism, cell diff erentiation, cell cycle 
progression, extracellular matrix mod-
eling, and infl ammatory signals.
All three isoforms of PPARs — PPARα, 
PPARγ, and PPARβ/δ — are highly 
expressed in mesangial cells, proximal 
tubules, and the medullary collecting 
duct.2 It has been demonstrated that 
PPARγ mRNA is reduced by 77% in 
glomeruli of diabetic mice,3 and insu-
lin-sensitizing TZDs are used for treat-
ing diabetes and metabolic syndrome. 
TZDs also provide renal protection in a 
rat model of type 2 diabetes with obesity 
by reducing proteinuria and glomerular 
and tubular kidney damage.4 In patients 
with type 2 diabetes, TZDs ameliorate 
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including fatty acid, triglyceride, and 
lipoprotein metabolism and reverse cho-
lesterol transport. Binding to PPARα by 
fatty acids, eicosanoids, and drug ligands 
leads to activation of numerous genes 
involved in the uptake and β-oxidative 
catabolism of fatty acids in the heart, 
kidney, and muscle. Increased diversion 
of fatty acids into β-oxidation decreases 
the availability of fatty-acyl-coenzyme A 
substrates for triglyceride synthesis and, 
therefore, reduces secretion of very-low-
density lipoprotein by the liver. PPAR 
agonists may also decrease triglyceride 
levels by increasing the expression of 
lipoprotein lipase in the liver (PPARα), 
in adipocytes and skeletal muscle 
(PPARγ), and in macrophages (PPARα 
and PPARγ). It is rather surprising that 
fenofi brate at the dose used in this model 
does not reduce triglycerides. Th is may 
be due to an increase in very-low-density 
lipoprotein synthesis through the path-
way of sterol regulatory element-binding 
protein-1c (SREBP1c), another PPAR-
targeted gene, rather than to a reduction 
in β-oxidation of fatty acid with PPARα 
agonists. Interestingly, serum total cho-
lesterol levels increase in db/db mice 
aft er 8 weeks of treatment. However, the 
lipid profi les of these mice show that the 
major cholesterol subfraction aff ected 
by fenofi brate is composed of increased 
high-density lipoprotein cholesterol. 
Th is could be a consequence of the fact 
that PPARα agonists increase cholesterol 
effl  ux from the peripheral tissue through 
the ABCA1 pathway, as demonstrated 
by Ruan et al.7 In addition, high-density 
lipoprotein reduces the low-density lipo-
protein infl ux into the cells by reducing 
the expression of CD36, and inhibiting 
the oxidation of low-density lipoprotein 
molecules. To further prove this, it will 
be important to investigate how PPARα 
specifically affects cholesterol reverse 
transport from peripheral tissues to the 
liver, and also how PPARα aff ects the 
liver x receptor–SREBP1c pathway that 
controls triglyceride synthesis. Perhaps 
a more specifi c PPARα agonist, which 
specifi cally targets the liver x receptor–
ABCA1 pathway rather than SREBP1c, 
will be required.
We have previously demonstrated that 
bezafi brate can override the suppression 
of infl ammatory cytokine-induced reduc-
tion of cholesterol effl  ux and prevent lipid 
accumulation in human mesangial cells.7 
Presumably, it also increases bile acid syn-
thesis and cholesterol absorption, which 
may contribute to dyslipidemia in patients 
with chronic renal diseases. We have also 
observed that bezafi brate inhibits NF-
κB activation and cytokine expression 
in human mesangial cells (unpublished 
data). It is possible that fenofi brate will 
improve the renal and cardiac protection 
afforded by bezafibrate by increasing 
both its anti-infl ammatory eff ects and 
the high-density lipoprotein-mediated 
cholesterol effl  ux pathway.
Diabetic glomerulosclerosis is char-
acterized by the accumulation of extra-
cellular matrix in the mesangium. 
Troglitazone, a PPARγ agonist, sup-
presses the secretion of type I collagen by 
mesangial cells in vitro; it also prevents 
mesangial expansion and glomerulo-
sclerosis in diabetic rats.9 Interestingly, 
Park et al. demonstrate in this issue that 
fenofi brate, a PPARα agonist, also reduces 
urinary albumin excretion and provides 
renal protection through the reduction of 
glomerular hypertrophy and mesangial 
matrix accumulation; this suggests that 
PPARα may represent a potential thera-
peutic target in the treatment of type 2 
diabetes and its renal complications.
Hypertension is commonly associated 
with insulin resistance, making blood 
pressure control an essential target for 
delaying the progression of diabetic 
nephropathy. Th e renoprotective eff ect of 
angiotensin-converting enzyme inhibi-
tors and angiotensin-2 receptor blockers, 
which is partially independent of blood 
pressure reduction, is well established in 
clinical practice. Th e antihypertensive 
effect of the PPARγ agonist rosiglita-
zone has been reported in patients with 
diabetes or obesity. Cytochrome P450-
dependent arachidonic acid metabolites 
may act as mediators in the regulation of 
vascular tone and renal function. It has 
been shown that both PPARα and cyto-
chrome P450 4A are expressed in renal 
proximal tubules. Treatment with either 
of the PPARα agonists clofibrate and 
bezafi brate increased cytochrome P450 
4A protein levels and production of 20-
hydroxyarachidonic acid (20-HETE)10 
and thus may ameliorate hypertension 
by restoring cytochrome P450-dependent 
arachidonic acid hydroxylase activities.
Diabetes is a major contributor to 
chronic kidney disease (CKD), and 
CKD patients are considered to be at 
the highest risk for cardiovascular dis-
ease. Clinical studies are beginning to 
emerge that support the hypothesis that 
the correction of dyslipidemia associated 
with CKD may slow the progression of 
cardiovascular disease. The emerging 
understanding of the interplay of insulin 
resistance, CKD, and cardiovascular dis-
ease is providing interesting possibilities 
for resolving some of the major metabolic 
consequences of the pandemic outbreak 
of type 2 diabetes. Th erefore, develop-
ment of strategies for early detection of 
insulin resistance and treatment with 
drugs that have multiple targets has great 
potential for tackling diabetes, CKD, and 
cardiovascular disease.
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